2. Search Result
Search Result
Results for "

KCNQ activator

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12343
    ML277
    1 Publications Verification

    CID-53347902

    		 Potassium Channel Cardiovascular Disease
    ML277 (CID-53347902) is a potent and selective activator of K(v)7.1 (KCNQ1) potassium channel activator (EC50=270 nM), rescues function of pathophysiologically important mutant channel complexes in human induced pluripotent stem cell-derived cardiomyocytes .
    ML277
  • HY-122114
    ICA-27243
    1 Publications Verification

    		 Potassium Channel Neurological Disease
    ICA-27243 is a selective, potent and orally active KCNQ2/Q3 potassium channel opener with an EC50 of 0.38 μM. ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 has antiepileptic and anticonvulsant effects .
    ICA-27243
  • HY-101396
    ICA-069673
    3 Publications Verification

    		 Potassium Channel Neurological Disease
    ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells .
    ICA-069673
  • HY-108587
    ICA 110381

    		Potassium Channel Neurological Disease
    ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. ICA 110381 is a KCNQ2/Q3 activator (EC50=0.38 μM) as well as KCNQ1 antagonist (IC50=15 μM) .
    ICA 110381
  • HY-157485
    Ebio1

    		Potassium Channel Others
    Ebio1 is a selective voltage-gated potassium channel KCNQ2 activator. Ebio1 activates KCNQ2 by generating an extended channel gate with greater conductance at a saturation voltage (+50 mV) .
    Ebio1
  • HY-108591
    L-364,373

    R-L3

    		 Potassium Channel Cardiovascular Disease
    L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .
    L-364,373
  • HY-123264
    RL648_81

    		Potassium Channel Neurological Disease
    RL648_81 is a specific KQT-like subfamily 2/3 (KCNQ2/3) activator with an EC50 of 190 nM. RL648_81 robustly shifts the V1/2 of KCNQ2/3 channels towards hyperpolarized potentials.RL648_81 does not shift the V1/2 of either KCNQ4 or KCNQ5.RL648_81 has?the?potential?for?neurologic disorders associated with neuronal hyperexcitability research .
    RL648_81
  • HY-145992
    KCNQ1 activator-1

    		Potassium Channel Cardiovascular Disease Neurological Disease
    KCNQ1 activator-1 (compound 5) is a potent activator of KCNQ1 channel with an EC50 of 1.69 μM. KCNQ1 activator-1 has the potential for the research of long QT syndrome (LQTS) .
    KCNQ1 activator-1
  • HY-179065
    VU0494372

    		Potassium Channel Cardiovascular Disease
    VU0494372 is an activator of potassium ion channel KCNQ1. VU0494372 can significantly enhance the cell surface expression and transport efficiency of KCNQ1. VU0494372 does not alter KCNQ1 mRNA levels and protein degradation rate, and has no significant cytotoxicity. VU0494372 can be used for research on cardiovascular conditions .
    VU0494372
  • HY-172141
    Ebio2

    		Potassium Channel Cardiovascular Disease
    Ebio2 is a potent KCNQ2 activator .
    Ebio2
  • HY-122504
    Linoleoyl glycine

    		Potassium Channel Neurological Disease
    Linoleoyl glycine is a modified polyunsaturated fatty acid. Linoleoyl glycine has activating effects on human KCNQ1/KCNE1 (hKCNQ1/hKCNE1) channels expressed in Xenopus oocytes .
    Linoleoyl glycine
  • HY-130070
    QO-40

    		Potassium Channel Neurological Disease
    QO-40, a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative, is a KCNQ2/KCNQ3 K + channels activator with an EC50 of 6.94 μM. QO-40 stimulated Ca 2+-activated K + current (IK(Ca)) with an EC50 value of 2.3 μM in pituitary GH3 lactotrophs .
    QO-40
  • HY-181128
    QO-83

    		Potassium Channel Neurological Disease
    QO-83, Retigabine analogue, is a voltage-gated potassium channel KCNQ2 (Kv7.2) activator with an EC50 of 0.56 μM. QO-83 binds to a single hydrophobic pocket of KCNQ2-CaM complex in closed conformation. QO-83 induces a negative shift in the voltage-dependent activation curve of KCNQ2 channels, increasing the channel's voltage sensitivity. QO-83 can be used for the research of epilepsies .
    QO-83
  • HY-108591R
    L-364,373 (Standard)

    R-L3 (Standard)

    		 Reference Standards Potassium Channel Cardiovascular Disease
    L-364,373 (Standard) is the analytical standard of L-364,373 (HY-108591). This product is intended for research and analytical applications. L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .
    L-364,373 (Standard)
  • HY-101396R
    ICA-069673 (Standard)

    		Potassium Channel Reference Standards Neurological Disease
    ICA-069673 (Standard) is the analytical standard of ICA-069673 (HY-101396). This product is intended for research and analytical applications. ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells .
    ICA-069673 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: